Compare — Georgia Financials

panel 2026-09-21Ask

Pooled trend

5 companies

Aggregate by year

GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series

Metric	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Revenue	99,798	138,439	153,458	178,646	217,984	217,493	206,613	146,795
EBITDA	12,953	8,728	8,356	11,993	10,583	11,916	-1,985	8,947
Net profit	6,213	9,633	13,178	8,473	12,881	13,785	-6,692	4,796
Total assets	60,666	72,146	105,897	130,712	149,193	159,990	183,385	110,120
n (companies reporting)	5	5	5	5	5	4	4	2

Per-company contribution by year

XLSX

GEL, thousands

Company	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Impexpharm	53,279	60,980	81,037	93,314	108,941	109,410	102,458	110,181
SmartPharm	0	13,790	19,785	23,780	32,208	33,896	31,577	36,614
Pharmaceutical House+	46,519	50,112	35,960	40,348	54,693	65,463	61,646	—
Iberi +	0	10,389	12,333	15,398	14,992	—	—	—
Akhali Khedva	0	3,168	4,344	5,807	7,150	8,724	10,932	—

Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.

Peer coverage varies by year — FY2017, FY2022–FY2024 pool fewer than the 5 picked companies (see the n row). A year is never dropped because one peer is missing.

Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.